New Obesity Drugs: Miracle Cure or Health Hazard?

New anti-obesity drugs mimicking GLP-1 and GIP hormones show promise for reducing body fat and providing cardio-metabolic benefits, including a reduced risk of heart attacks and diabetes. However, questions persist regarding their safety, potential adverse effects, and the risk of rebound obesity upon discontinuation. The Director General of Health Services has justified recent prescribing restrictions due to potential misuse by uninformed practitioners.

India, known as the 'pharmacy of the world,' is set to play a significant role as the patent for semaglutide, a key GLP-1 agonist, nears expiration. Indian manufacturers are poised to flood the market with generic versions, offering substantial cost reductions. This development aligns with the Doha Declaration, which permits patent relaxations for public health threats like cardiovascular diseases and diabetes, which are major causes of premature death globally.

While these drugs effectively combat inflammation and abdominal fat, common in Indian populations, they carry notable side effects. These include gastrointestinal issues, mental health disturbances, visual problems, and a significant risk of sarcopenia (loss of skeletal muscle) in 25-40% of users. This is particularly concerning for Indians who typically have lower lean muscle mass, increasing the risk of falls.

Discontinuation often leads to weight regain and a loss of health benefits, especially for those not maintaining healthy lifestyles. Prolonged therapy, with its associated costs and risks, may be necessary. Regulatory caution remains crucial as the long-term benefits and risks are further assessed in diverse patient populations.